research team standing around screen in a laboratory environment
From left: Professor Chng Wee Joo, Director of the National University Cancer Institute, Singapore and Senior Principal Investigator at the Cancer Science Institute of Singapore, NUS; Dr Edward Chow, Principal Investigator at the Cancer Science Institute of Singapore, NUS; Dr Masturah Rashid, recent PhD graduate from NUS and first author of the study; and Professor Dean Ho, Director of the Singapore Institute for Neurotechnology at NUS.

Credit: National University of Singapore

Personalised drug treatment

AI approach to help myeloma patients

A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug combination for a patient quickly.

Applying the platform towards drug resistant multiple myeloma, a type of blood cancer, the researchers were able to establish new effective drug combinations, as well as identify the patients who may be more responsive to these treatments in under a week.

Existing methods for designing drug combinations typically involve testing arbitrary combinations of commonly used drugs or incorporating new targeted therapies into established drug combinations. Bortezomib-containing drug combinations are currently used as the first and second-line treatment for multiple myeloma. However, most patients inevitably become resistant to these drugs and new combinations need to be established. While some newer combinations have shown to be effective for some patients, rapid identification of an optimal personalised treatment for a specific patient from an infinite span of possible drug combinations remains a challenge.

Customising the optimal drug ‘cocktail’ for every patient using AI

The efficiency of this platform in utilising small experimental data sets enables the identification of optimal drug combinations in a timely and cost-efficient manner, which marks a big leap forward in the field of personalised medicine

Kai-Hua Chow

The research team comprising clinicians, engineers and molecular biologists from NUS have therefore developed the AI technology platform, Quadratic Phenotypic Optimisation Platform (QPOP), to speed up drug combination design and to identify the most effective drug combinations targeted at individual patients using small experimental data sets. With just a small amount of blood or bone marrow sample from patients, the platform is able to map the drug response that a set of drug combinations will have on the specific patient’s cancer cells. From an initial pool of 114 FDA-approved drugs, QPOP was able to identify a series of effective drug combinations, including a completely novel and unexpected combination that outperformed the standard of care regimen for relapsed myeloma. The performance of the novel combination was validated against 13 patient samples. QPOP was also used to fine-tune dosage ratios of the novel combination for optimal effectiveness.

Using four other patient samples, the research team further demonstrated that QPOP was able to evaluate and rank the novel combination against the other two current clinically used drug combinations. The novel combination was found to be the most effective treatment option for two of the myeloma patient samples tested. While the novel combination was not the most effective for all four patient samples, QPOP was able to match the best drug combination to each patient, hence demonstrating proof-of-concept for personalised medicine. The ability of QPOP to simultaneously incorporate optimisation and personalisation of drug combinations with unprecedented speed opens the door to improving patient accessibility to personalised medicine. New combination therapies can also significantly broaden the spectrum of effective treatments for patients.

Dr Edward Kai-Hua Chow, Principal Investigator at the Cancer Science Institute of Singapore, NUS, who led the study, said, “QPOP revolutionises the way in which drug combinations are designed and represents a key area in healthcare that can be transformed with AI. The efficiency of this platform in utilising small experimental data sets enables the identification of optimal drug combinations in a timely and cost-efficient manner, which marks a big leap forward in the field of personalised medicine.” The other NUS research institutes involved in the development of QPOP include the Singapore Institute for Neurotechnology (SINAPSE) and the Biomedical Institute for Global Health Research and Technology (BIGHEART). The findings were published in Science Translational Medicine.

The team is now working towards translating this work into the clinic. They will look into recruiting patients for prospective clinical trials related to QPOP and other artificial intelligence platforms in 2019, as well as expand the application of the platform into other disease areas.


Source: National University of Singapore

13.08.2018

Read all latest stories

Related articles

Diagnostic tests followed by personalized medicine

A new genre of medical tests - which determine whether a medicine is right for a patient's genes - are paving the way for increased use of personalized medicine, according to the cover story in the…

Oral vaccination against pancreatic tumours

The world’s first gene cancer therapy study of an innovative oral vaccine is underway at the Surgical Clinic of Heidelberg University Hospital.

Open source

Machine Learning tool could help choose cancer drugs

The selection of a first-line chemotherapy drug to treat many types of cancer is often a clear-cut decision governed by standard-of-care protocols, but what drug should be used next if the first one…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Blood collection

SARSTEDT - S-Monovette - Venous Blood Collection

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH